Health ❯ Regulatory Affairs ❯ FDA

Drug Approval Process

Orphan Drug Designation Patient Safety New Drug Application Recall Procedures Benefit-Risk Assessment Safety Warnings

Fulcrum Halts Pociredir Development After FDA Flags PRC2 Cancer Risk

The FDA concluded PRC2-targeting therapies carry similar cancer risks, leaving no viable regulatory path for pociredir.